A new way of tackling ROP

Article

A potential new treatment approach for retinopathy of prematurity (ROP) may be possible now that insulin-like growth factor binding protein 3 (IGFBP-3) has been found to play an important role in promoting the development of retinal blood vessels.

A potential new treatment approach for retinopathy of prematurity (ROP) may be possible now that insulin-like growth factor binding protein 3 (IGFBP-3) has been found to play an important role in promoting the development of retinal blood vessels, according to researchers from the University of Florida and Harvard Medical School, USA.

IGFBP-3 was already known to play a vital role in the development of various body tissues but, a study led by Maria Grant, MD of the University of Florida found that the protein also activates stem cells and other reparative cells of bone marrow and the lining of blood vessels. The research team infused IGFBP-3 into one eye of nine mice and then placed the mice into a high-oxygen chamber. It was found that the eyes treated with the protein demonstrated more normal retinal blood vessel development.

In a prospective study conducted by Harvard Medical School, it was found that IGFBP-3 levels were lower in infants with ROP than in healthy children, suggesting that the protein helps prevent oxygen-induced blood vessel loss and promotes vascular re-growth.

A study is now being conducted to evaluate whether IGFBP-3, used in conjunction with IGF-1, can help prevent ROP in infants.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.